SpringerLink
Log in

Controversial BRCA1 allelotypes in commonly used breast cancer cell lines

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Favy DA, Rio P, Maurizis JC et al (1999) Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines. Biochem Biophys Res Commun 258(2):284–291

    Article  CAS  PubMed  Google Scholar 

  2. Abbott DW, Thompson ME, Robinson-Benion C et al (1999) BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 274(26):18808–18812

    Article  CAS  PubMed  Google Scholar 

  3. Chai Y, Chipitsyna G, Cui J et al (2001) c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. Oncogene 20(11):1357–1367

    Article  CAS  PubMed  Google Scholar 

  4. Trenz K, Landgraf J, Speit G (2003) Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation. Breast Cancer Res Treat 78(1):69–79

    Article  CAS  PubMed  Google Scholar 

  5. Kroupis C, Stathopoulou A, Zygalaki E et al (2005) Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem 38(1):50–57

    Article  CAS  PubMed  Google Scholar 

  6. El-Tanani MK, Campbell FC, Crowe P et al (2006) BRCA1 suppresses osteopontin-mediated breast cancer. J Biol Chem 281(36):26587–26601

    Article  CAS  PubMed  Google Scholar 

  7. Cousineau I, Belmaaza A (2007) BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination. Cell Cycle 6(8):962–971

    CAS  PubMed  Google Scholar 

  8. Francisco DC, Peddi P, Hair JM et al (2008) Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and nonmalignant MCF-10A cells. Free Radic Biol Med 44(4):558–569

    Article  CAS  PubMed  Google Scholar 

  9. Yu X, Luo Y, Zhou Y et al (2008) BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4–p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. Int J Oncol 33(3):555–563

    CAS  PubMed  Google Scholar 

  10. Holt JT, Thompson ME, Szabo C et al (1996) Growth retardation and tumour inhibition by BRCA1. Nat Genet 12(3):298–302

    Article  CAS  PubMed  Google Scholar 

  11. Kytola S, Rummukainen J, Nordgren A et al (2000) Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyoty**. Genes Chromosomes Cancer 28(3):308–317

    Article  CAS  PubMed  Google Scholar 

  12. Davidson JM, Gorringe KL, Chin SF et al (2000) Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer 83(10):1309–1317

    Article  CAS  PubMed  Google Scholar 

  13. Roschke AV, Tonon G, Gehlhaus KS et al (2003) Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63(24):8634–8647

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. M. Seto for providing reagents and helpful discussion. This work was funded by grants from Department of Defense Breast Cancer Research Program Predoctoral Traineeship Awards BC083057 to M.M., the Ministry of Education, Science, Sports and Culture, Japan to Y.H., the Avon Foundation, Susan G. Komen for the Cure, the Mary Kay Ash Charitable Foundation, the Stewart Trust Fund, National Institutes of Health (CA109274 and CA88843), Flight Attendant Medical Research Institute (FAMRI), and the Breast Cancer Research Foundation to B.H.P, and FAMRI to H.K. Conflict of interest statement: B.H.P. is a consultant for GlaxoSmithKline and Horizon Discovery Ltd and has received research funding from GlaxoSmithKline.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Aichi Medical University School of Medicine, 21 Yazako Karimata, Research Building Room 362, Nagakute, Aichi, 480-1195, Japan

    Sivasundaram Karnan, Yoshitaka Hosokawa & Hiroyuki Konishi

  2. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, 1650 Orleans St., CRB Room 1M42, Baltimore, MD, 21231, USA

    Morassa Mohseni, Yuko Konishi, Akina Tamaki, Ben H. Park & Hiroyuki Konishi

Authors
  1. Sivasundaram Karnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morassa Mohseni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuko Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akina Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshitaka Hosokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ben H. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ben H. Park or Hiroyuki Konishi.

Additional information

Sivasundaram Karnan and Morassa Mohseni contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

(PDF 29 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karnan, S., Mohseni, M., Konishi, Y. et al. Controversial BRCA1 allelotypes in commonly used breast cancer cell lines. Breast Cancer Res Treat 119, 249–251 (2010). https://doi.org/10.1007/s10549-009-0465-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0465-3

Keywords

Search

Navigation